THERAPEUTIC STRATEGY COMBINING INTRAVENOUS CYCLOPHOSPHAMIDE FOLLOWED BY ORAL MYCOPHENOLATE MOFETIL TO TREAT SEVERE OR WORSENING INTERSTITIAL LUNG DISEASE ASSOCIATED WITH SYSTEMIC SCLEROSIS

被引：0
|
作者：
Duchange, Al [1 ]
Mouthon, L. [2 ]
Berezne, A. [2 ]
Morell-Dubois, S. [1 ]
Hatron, P. Y. [1 ]
Guillevin, L. [2 ]
Hachulla, E. [1 ]
Launay, D. [1 ]
机构：
[1] Hop Claude Huriez, Ctr Reference Sclerodermie, CHRU, Serv Med Interne, Lille, France
[2] Hop Cochin, Ctr Reference Vasc & Sclerodermie, Serv Med Interne, F-75674 Paris, France
来源：
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY | 2010年 / 28卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S165 / S165
页数：1
相关论文
共 50 条
  • [1] Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis:: A retrospective multicenter open-label study
    Berezne, Alice
    Ranque, Brigitte
    Valeyre, Dominique
    Brauner, Michel
    Allanore, Yannick
    Launay, David
    Le Guern, Veronique
    Kahn, Jean-Emmanuel
    Couderc, Louis-Jean
    Constans, Joel
    Cohen, Pascal
    Mahr, Alfred
    Pagnoux, Christian
    Hachulla, Eric
    Kahan, Andre
    Cabane, Jean
    Guillevin, Loic
    Mouthon, Luc
    JOURNAL OF RHEUMATOLOGY, 2008, 35 (06) : 1064 - 1072
  • [2] Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease
    Athanasios Koutroumpas
    Athanasios Ziogas
    Ioannis Alexiou
    Georgia Barouta
    Lazaros I. Sakkas
    Clinical Rheumatology, 2010, 29 : 1167 - 1168
  • [3] Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease
    Koutroumpas, Athanasios
    Ziogas, Athanasios
    Alexiou, Ioannis
    Barouta, Georgia
    Sakkas, Lazaros I.
    CLINICAL RHEUMATOLOGY, 2010, 29 (10) : 1167 - 1168
  • [4] Treatment of systemic sclerosis with severe interstitial lung disease (ILD) unresponsive to cyclophosphamide (CYC) with mycophenolate mofetil (MMIT).
    Mouthon, L
    Valeyre, D
    Brauner, M
    Lamberto, C
    André, MH
    Mahr, A
    Guillevin, L
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S559 - S559
  • [5] Mycophenolate mofetil as a therapeutic agent for interstitial lung diseases in systemic sclerosis
    Ueda, Takahiro
    Sakagami, Takuro
    Kikuchi, Toshiaki
    Takada, Toshinori
    RESPIRATORY INVESTIGATION, 2018, 56 (01) : 14 - 20
  • [6] Comparative effectiveness of mycophenolate mofetil versus cyclophosphamide in systemic sclerosis-related interstitial lung disease
    Gkiouras, Konstantinos
    Grammatikopoulou, Maria G.
    Simopoulou, Theodora
    Daniil, Zoe
    Bogdanos, Dimitrios P.
    CLINICAL RHEUMATOLOGY, 2021, 40 (08) : 3379 - 3380
  • [7] Comparative effectiveness of mycophenolate mofetil versus cyclophosphamide in systemic sclerosis-related interstitial lung disease
    Konstantinos Gkiouras
    Maria G. Grammatikopoulou
    Theodora Simopoulou
    Zoe Daniil
    Dimitrios P. Bogdanos
    Clinical Rheumatology, 2021, 40 : 3379 - 3380
  • [8] Importance of mycophenolate mofetil for treatment of interstitial lung disease in systemic sclerosis
    Schneider, Udo
    Siegert, Elise
    Glaser, Sven
    Kruger, Klaus
    Krause, Andreas
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2021, 80 (09): : 868 - 878
  • [9] Outcome of systemic sclerosis associated interstitial lung disease treated with intravenous cyclophosphamide
    Abhishek, Abhishek
    Yazdani, Ramin
    Pearce, Fiona
    Regan, Marian
    Lim, Ken
    Hubbard, Richard
    Lanyon, Peter
    CLINICAL RHEUMATOLOGY, 2011, 30 (08) : 1099 - 1104
  • [10] Outcome of systemic sclerosis associated interstitial lung disease treated with intravenous cyclophosphamide
    Abhishek Abhishek
    Ramin Yazdani
    Fiona Pearce
    Marian Regan
    Ken Lim
    Richard Hubbard
    Peter Lanyon
    Clinical Rheumatology, 2011, 30
12345